These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28627808)

  • 21. Value-Based Pharmaceutical Contracts: Value for Whom?
    Kannarkat JT; Good CB; Parekh N
    Value Health; 2020 Feb; 23(2):154-156. PubMed ID: 32113619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Green Supply Chain Decisions Under Different Power Structures: Wholesale Price vs. Revenue Sharing Contract.
    Liu X; Du W; Sun Y
    Int J Environ Res Public Health; 2020 Oct; 17(21):. PubMed ID: 33105880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments.
    Antonanzas F; Juárez-Castelló C; Lorente R; Rodríguez-Ibeas R
    Pharmacoeconomics; 2019 Dec; 37(12):1469-1483. PubMed ID: 31535280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK.
    Ogbighele E
    IDrugs; 2010 May; 13(5):317-20. PubMed ID: 20432188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retailer Stackelberg game in a supply chain with pricing and service decisions and simple price discount contract.
    Sadjadi SJ; Asadi H; Sadeghian R; Sahebi H
    PLoS One; 2018; 13(4):e0195109. PubMed ID: 29649315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia.
    Darbà J; Ascanio M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):743-748. PubMed ID: 30821532
    [No Abstract]   [Full Text] [Related]  

  • 27. Examining the link between price regulation and pharmaceutical R&D investment.
    Vernon JA
    Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers.
    Morgan SG; Thomson PA; Daw JR; Friesen MK
    Health Policy; 2013 Oct; 112(3):248-54. PubMed ID: 23809914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value-based differential pricing: efficient prices for drugs in a global context.
    Danzon P; Towse A; Mestre-Ferrandiz J
    Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk sharing agreements: what lessons from Italy?
    Garattini L; Casadei G
    Int J Technol Assess Health Care; 2011 Apr; 27(2):169-72. PubMed ID: 21429288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Financial valuation of incentive arrangements in managed care contracts: a real options approach.
    Maurer RT
    J Health Care Finance; 2001; 28(1):39-60. PubMed ID: 11669292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New drugs: money-back guarantee?].
    Steenhoek A; Koopmanschap MA; Franken MG; Rutten FF
    Ned Tijdschr Geneeskd; 2011; 155():A2042. PubMed ID: 21262015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.
    Garrison LP; Carlson JJ; Bajaj PS; Towse A; Neumann PJ; Sullivan SD; Westrich K; Dubois RW
    Am J Manag Care; 2015 Sep; 21(9):632-40. PubMed ID: 26618366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Value-based performance arrangements for chronic conditions: an economic simulation of Medicaid Drug Rebate Program reforms.
    Quinn C; Ciarametaro M; Sils B; Phares S; Trusheim MR
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):535-546. PubMed ID: 36987666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Risk-sharing agreements: choice of study design and assessment criteria].
    Launois R; Ethgen O
    Ann Pharm Fr; 2013 Sep; 71(5):346-57. PubMed ID: 24075705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.
    Neumann PJ; Chambers JD; Simon F; Meckley LM
    Health Aff (Millwood); 2011 Dec; 30(12):2329-37. PubMed ID: 22147861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of hospitalizations prior to and after conversion to a rebate pharmaceutical in depression patients in Germany.
    Kostev K; May U; Ott C; Paul M; Schetschok K; Tingelhoff M; Claus C; Waehlert L
    Int J Clin Pharmacol Ther; 2013 May; 51(5):416-22. PubMed ID: 23547855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years' Experience.
    Ludwig S; Dintsios CM
    Value Health; 2016 Dec; 19(8):1016-1025. PubMed ID: 27987628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coordinating a supply chain with a loss-averse retailer and effort dependent demand.
    Li L; Wang Y
    ScientificWorldJournal; 2014; 2014():231041. PubMed ID: 25197696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.